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Abstract 
Background: Hepatocellular carcinoma (HCC) is a primary liver 
cancer. This study assessed the factors associated with the survival outcome 
of HCC on supportive care. Methods: This was a prospective cohort study 
carried out from January 2010 to June 2016 on cases of HCC recruited into a 
cancer data registry. Clinical, laboratory and survival outcomes were obtained. 
Data obtained were analyzed using descriptive and inferential statistics.  
Results: A total of 149 cases were analyzed: 120 (80.5%) males and 29 
(19.5%) females. Age range was 18-87years, with mean (SD) being 45.0 
(14.3) years. Identifiable aetiological factors were hepatitis B and C viruses, 
alcohol and herbal preparations in 94% while no risk factor was identified in 
6%. Some risks co-occurred in multiples in 71.2% of cases. The overall 
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median survival was 20 days, and general survival was 59.1% at two weeks, 
33.6 % at one month, and only 7.3% surviving beyond thirty one days to two 
years. The survival of cases, according to the Child-Pugh (CTP) class, was 
CTP A: 36 days (ranged 4 to 730 days), CTP class B: 22 days (ranged 1 to 210 
days) and CTP class C: 14 days (ranged 2 to 660 days). Higher proportion of 
young cases was HBsAg positive. Factors significantly associated with 
survival outcome included older age, female sex, abdominal pain, jaundice, 
elevated creatinine, bilirubin, AST, ALT, white cell count and hyponatreamia.  
Conclusion:  Overall survival outcome among cases of HCC was poor. It is 
necessary to prevent HBV, reduce alcohol use, detect and treat HCC early.  
 
Key words: Factors, survival outcome, Hepatocellular carcinoma 
 
Introduction 
Hepatocellular carcinoma (HCC) is a primary malignancy of 
hepatocytes and it is a common liver cancer with dismal prognosis (Okonkwo 
et al. 2011). HCC usually presents with a right upper abdominal mass, pain 
and weight loss. The disease is rapidly fatal within a period of six months and 
some patients die during hospital admission from complications of the disease 
(Ndububa et al. 2010 and Yang et al. 2017). Treatment modalities in advanced 
countries of the world show some rewarding results as the five year survival 
period following a liver resection for HCC could be up to 26% (Neeff et al. 
2009). Liver transplantation, on the other hand, has been reported in one study 
to have a ten years post-surgery survival rate of 51.3% (Tinoco-Gonzalez et 
al. 2016). At the late stages, median survival periods of 9 months and 6.8 
months respectively were reported among untreated cases from two studies 
(Cabibbo et al. 2012 and Giannini et al. 2015).  
There are reports that clinical parameters as well as electrolyte and 
liver function abnormalities affect the survival of HCC.  A study reported that 
female gender, ascites and a multi-nodular liver masses were independent 
predictors of survival among untreated cases of HCC (Cabibbo et al. 2012). 
Another study reported a low serum albumin, elevation of both bilirubin and 
international normalized ratio (INR) as being significantly associated with 
high mortality among untreated cases of HCC. The median survival period of 
patients with HCC using the Child-Pugh class has also been observed to 
reduce progressively according to worsening liver disease severity (Cabibo et 
al. 2012). Other indices that contribute to a short survival time are a positive 
HBsAg status, high levels of alpha-fetoprotein, alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST). (Abbas et al. 2008, Changchien 
et al. 2008 and Zhang et al. 2014).   
Most cases of HCC in Nigeria usually present at a late stage of the 
disease when virtually nothing can be done other than giving supportive care. 
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Hepatitis B virus (HBV) infection is also the commonest cause of HCC in 
Nigeria, with some contributions from hepatitis C (HCV) infection and 
alcohol consumption (Okonkwo et al. 2011). There are almost no reports to 
date among untreated cases of HCC in Nigeria that have studied the influence 
of laboratory and clinical parameters on the survival of HCC on supportive 
care. It is therefore important to identify clinical and pathological 
characteristics in relation to outcomes of cases on supportive care in Nigeria. 
 
Methods       
This was a hospital-based study of cases of HCC on supportive care 
that presented at a late stage to the Obafemi Awolowo University Teaching 
Hospital in Nigeria. They were prospectively and consecutively recruited into 
an HCC cancer data registry (HCDR) of the Gastro-intestinal unit of the 
hospital after an informed consent from January 2010 to June 2016. A total of 
174 cases were seen within the study period. Twenty five (25) cases were 
excluded from the analysis. Two (2) of those excluded were at the advanced 
stage and were treated with Sorafenib, while 23 cases were excluded due to 
incomplete data.  
Hepatocellular carcinoma was diagnosed based on history and clinical 
examination findings suggestive of the disease as well as radio-diagnostic 
features, cytology/histology and or tumour marker. Detailed findings on 
clinical examination, including the presence or absence of ascites, as well as 
laboratory tests, which included haematology, chemistry, coagulation tests 
and serological tests for hepatitis B and C viruses, were carried out at 
presentation when the cases were seen and the diagnosis of HCC was made. 
Other lifestyle habits, such as herbal use and alcohol consumption, were 
quantified and a value up to 50 grams per day for up to 10 years was considered 
a significant value for those that drank alcohol (Ndububa et al. 2010). 
The cases were followed up at diagnosis in the clinic, while on 
admission and after discharge from the hospital. Outcome was taken as the 
time of death during clinic attendance, on admission or after discharge from 
the hospital. Total number of days spent was taken as the time from first 
contact in the hospital when the diagnosis of HCC was made to the time patient 
died. The date of death was obtained through phone contact to the relatives for 
cases that were managed on outpatient basis or discharged cases from the 
hospital. Where phone contact was not possible, the date of death was taken 
as the day after the last clinic visit. Details of bio-data as well as physical and 
systemic examination findings in the abdomen and laboratory tests were 
recorded in a proforma. The study was reviewed and approved by the 
Institutional Review Board of our hospital (Number: IRB/IEC/0004553 and 
NHREC/27/02/2009). 
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Statistical analysis 
The data collected were entered into and analyzed using SPSS version 
20. Simple descriptive and inferential statistics were performed and the results 
presented. Survival outcome was calculated and presented as in the first 
fourteen (14) days, between first fifteen days and one month, and after one 
month to two years respectively. Clinical and laboratory parameters of the 
cases were computed as mean values and presented according to the survival 
periods. Comparison of the clinical and laboratory indices was made for the 
various periods of death. Cases were divided into two age groups, those aged 
40 years and below and those aged 41 years and above, to differentiate them 
into young and old cases of HCC according to previous studies from Asia and 
Europe respectively (Chang et al. 2008 and Niederie et al. 2012). Clinical and 
laboratory indices were also compared for the two age groups. Kaplan-Meier 
survival analysis was done to determine the mean and median survival time 
after diagnosis for cases by age and sex. A p value of < 0.05 was accepted as 
significant. 
 
Results 
A total of 149 cases were analyzed. Their ages ranged from 18-87 years 
with a mean age (SD) of 45.0 (14.3) years.  There were 120 (80.5%) males 
and 29 (19.5%) females with an M: F ratio of 4:1. Sixty two artisans, (41.6%) 
and 37 traders (24.8%) constituted the majority of the cases. Sixty-nine 
(46.3%) were young while 80 (53.7%) were old cases of HCC. Aetiological 
factors identified were hepatitis B infection in 99 (66.4%) while the number 
that took alcohol in significant quantity was 20 (13.4%), HCV was 3 (2%) 
while the number that took local herbal remedies was 34 (22.8 %). Overlap of 
risk factors also occurred in various combinations (Table1).  
Table 1.Basic Demographic Characteristics and risk factors of Cases 
Variables No (%) 
 Sex  
                                  Male  120 (80.5) 
                                  Female  29 (19.5) 
Occupation               Unemployed 21 (14.1) 
                                 Traders 37 (24.8) 
                                 Civil servants 29 (19.5) 
                                 Artisans 62 (41.6) 
Ethnicity                   Yoruba 136(91.3) 
                                  Igbo  7(4.7) 
                                 *Others 6(4.0) 
Marital status            Single  24(16.1) 
                                 Married  119(79.9) 
                                 Divorced  2(1.3) 
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                                 Widow  4(2.7) 
 HBsAg                    Negative  50(33.6) 
                                 Positive  99(66.4) 
 HCV                       Negative 146(98.0) 
                                 Positive    3 (2.0) 
 Alcohol                   Non drinkers  91(61.1) 
                                 Significant alcohol drinkers  20(13.4) 
                                 Non- significant alcohol drinkers 38(25.5) 
Mortality pattern      First 14 days                                                                                       61(40.9)
                                 15days to 30 days                           38 (25.5) 
                                  31 days to 730 days 50 (33.6) 
**Identifiable Risks factors       
                                 HBV+ HCV+ Alcohol    33(22.2) 
                                 Herbal   medications                                                                34(22.8) 
                                 Herbal + HBV+ HCV+ Alcohol     73(48.9) 
                                 No risk factor identified 9(6.04) 
Keys:  HCV = Hepatitis C Virus, HIV = Human Immunodeficiency Virus 
*Other tribes: Ebira=1, Igala=1, Idoma=1, Edo=1 & Urhobo =2.** Multiple response 
 
The mortality pattern showed that out of the 149 cases, 52 (34.9%) 
died while on hospital admission, 55 (36.9%) were admitted and died after 
discharge, while 42 (28.2%) were managed on an outpatient basis and died at 
home.  
The  time of death showed that 61(40.9%) died within the first 14 days, 
while 38 (25.5%) and 50 (33.6%) died between fifteen days and one month, 
and after one month and two years respectively (Table 1). The overall median 
survival for all cases was 20 days, while general survival was 59.1% at two 
weeks, 33.5% at one month and only 7.3 % surviving beyond thirty- one days 
to two years respectively. The median survival, according to the CTP classes, 
were: CTP class A: 36 days (ranged 4 to 730 days), CTP class B: 22 days 
(ranged 1 to 210 days) and CTP class C: 14 days (ranged 2 to 660 days). 
The clinical history and physical examination of cases showed that a 
higher proportion of cases that died early had statistically significant clinical 
features of a decompensated HCC (abdominal pain, p = 0.02; yellow sclera, p 
= 0.001 and jaundice on examination, p = 0.01) than cases that died afterwards 
(Table 2).  
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Table 2. Clinical presentation and examination findings and their relationship to patients’ 
time of death. 
 Early death Late early Late  
                                                             
Patients’ complaints 
and examinations findings 
(first 14days) 
No 
death (15-30)days) 
No 
>30 days death 
No 
p-value 
Upper abdominal pain           Yes                           50 38 40 0.02 
                                        No 11 0 10  
Weight loss                            Yes 53 32 40 0.62 
                                        No 8 6 10  
Yellow sclera                         Yes 48 22 26 0.009 
                                        No 13 16 24  
Abdominal swelling              Yes                                       50 33 41 0.79 
                                        No 11 5 9  
Jaundice on examination      Yes            51 27 29 0.01 
                                         No 10 11 21  
Ascites                                 None 12 11 19 0.102 
                                        Present 49 27 31  
PV Thrombosis                     Yes                   1 3 4 0.194 
                                      No 60 35 46  
CTP Class                              A 3 5 14 0.002 
                                       B 20 17 20  
                                      C 38 16 16  
KEYS: PV= Portal vein, CTP= Child-Pugh class 
 
The cases of HCC that died within the first 14 days had statistically 
significant elevated levels of serum creatinine, p = 0.05, total and conjugated 
bilirubin, p = 0.001; elevated AST; p = 0.02; ALT, p = 0.001 and 
hyponatremia, p = 0.001 compared with those that died later (Table 3).   
  Table 3Laboratory value and their relationship to patients’ time of death 
Laboratory 
variables 
Early death (first 14days)  
Mean (+SD) 
Late early death(15-30) 
days Mean (+SD) 
 Late >30 days death               
Mean (+SD) 
   p-value 
WBC(cmm)  8756.4+5542.3 7927+4528.6 8281.0+4051.8 0.71 
K+  (mmol/l) 6.6+18.6 3.6+0.5 4.6+4.3 0.50 
Na+ (mmol/l) 128.1+6.5 129.1+5.5 131.9+5.8 0.001 
Urea (mmol/l) 8.4+6.6 6.3+2.8 7.4+7.0 0.27 
Creatinine  (umol/l)   126.1+75.6 99.9+32.4 102.1+42.6 0.053 
B1  (umol/l) 181.9+165.3 92.1+106.0 60.6+69.8 0.000 
B2  ( umol/l) 137.9+146.6 68.6+91.1 45.9+62.4 0.000 
AST  ( iu/l) 105.1+61.8 80.7+50.1 65.5+43.8 0.001 
ALT  ( iu/l) 41.8+35.0 28.4+21.3 33.9+28.4 0.02 
ALK   (iu/l) 446.0+320.0 352.4+237.7 352.0+282.0 0.24 
Albumin (g/l) 30.1+6.1 31.5+6.0 32.7+6.4 0.107 
INR 1.5+0.6 1.4+0.4 1.4+0.4 0.36 
KEYS: WBC= White blood cells, K+ =potassium, Na+ = Sodium, B1 =Total bilirubin, B2 
=Conjugated bilirubin, AST=Aspartate aminotransferase, ALT=Alanine aminotransferase, 
INR=International normalized ratio, ALK= Alkaline phosphatase.      
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When the cases were divided into old and young HCC, a higher 
proportion of young cases with HCC had a statistically significant positive test 
for HBsAg than old cases of HCC, p = 0.005 [HCC cases: 40 years and below, 
HBsAg positive 54 (54.5%), HBsAg negative 15 (30%), HCC cases 41 years 
and above, HBsAg positive 45 (45.5%), HBsAg negative 35 (70%)].  
Kaplan-Meier survival analysis showed that the mean and median 
survival time by age was 111.2 days vs. 162.4 days, 35 days vs. 34 days for 
young and old cases respectively; while by sex, it was 99 days vs. 124.8 days, 
34 days vs. 35 days for males and females respectively (Table 4). Kaplan-
Meier survival analyses showed that 50% were dead by 35 days of care among 
young cases (Figure 1), while 50% were dead by 34 days of care in males 
(Figure 2). 
Table 4.The comparison of mean and median survival time of HCC patients by age and sex 
Variable                           Mean                      Median  
Age group (years) Estimate  S.E. 95% CI Estimate  S.E. 95%CI 
≤40 111.2 34.3 44.0 178.4 35.0 7.2 21.0 49.0 
>40 162.4 43.4 77.4 247.4 34.0 8.2 18.0 50.0 
Sex                          Mean                     Median  
Male  99.0 17.5 64.7 133.3 34.0 7.0 20.4 47.6 
Female  124.8 53.2 20.6 229.0 35.0 8.7 17.9 52.1 
 
 
Figure 1: Survival analysis of young and old HCC cases 
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Figure 2:   Survival analysis of HCC cases by sex  
                                                      
The mean and median survival time for cases of HCC with neutrophil 
cell count suggestive of infection was significantly shorter than those without 
infection 31.0 and 17.5 days vs. 59.7 and 23 days respectively, p = 0.05 (Table 
5). Significant factors associated with survival outcome were older age, female 
sex, abdominal pain, jaundice, elevated creatinine, bilirubin, AST, ALT, 
neutrophil cell count and hyponatreamia. 
Table 5. Clinical and laboratory qualities of HCC cases 
Parameters  Number Mean duration alive Median  p-value 
Bilirubin, umol/l    <171 106 48.26 21.5  
                                 >171 43 33.16 12.0 0.356 
Neutrophil             <70% 67 59.69 23.0  
                                >70% 82 31.01 17.5 0.053 
Liver   Failure         Yes 31 21.68 14.0  
                                  No  118 49.75 21.0 0.123 
HBsAg                     Positive 99 35.83 19.0  
                                Negative 47 62.09 21.0 0.103 
INR                          <1.3 74 46.41 21.0  
                                  >1.4 75 41.44 18.0 0.738 
Albumin g/l              <35 108 46.90 19.5  
                                  >36 41 36.02 25.0 0.512 
KEYS: CTP=Child-Pugh class, INR= International normalized ratio 
 
Discussion 
This study assessed the factors associated with the survival outcome of 
patients with HCC in a cohort of Nigerian patients on supportive care. 
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The survival pattern showed that 59.1% were alive at two weeks, 33.6 
% at one month, and only 7.3% surviving beyond thirty one days to two years. 
This is in sharp contrast to cases of HCC from Europe, where those that 
presented late without treatment survived for a median period of 7 to 9 months 
(Cabbibo et al. 2012 and Giannini et al. 2015).  This observed difference may 
be due to the state of the cases at presentation, as many presented late with 
infection and hepato-renal failure. Studies from developed countries have 
reported that survival of HCC is affected by low serum sodium, high levels of 
alkaline phosphatase, AST, ALT, bilirubin, INR, and low albumin, as well as 
the presence of ascites (Abbas et al. 2008, Changchien 2008 and Zhang et al. 
2014,).  This paper shows similar findings to reports from other studies, even 
though INR and patients with ascites did not contribute significantly to death 
among those that died early. The cases that died early from the findings in this 
cohort had, in addition, elevated creatinine. The reason for this could probably 
have been due to hepato-renal failure. Also, the serum sodium showed that 
hyponatreamia contributed significantly to death, more especially among 
cases that died early. Studies from other countries have reported similar 
findings with excess mortality in patients with CLD having hyponatreamia  
(Jen et al. 2010 and Moini et al. 2011). 
This study reported that survival was better for old and female cases 
of HCC than for young and male cases. The implication of these findings may 
require further research. However, some studies from Asia and Europe 
reported contrary findings that survival was similar for both old and young 
cases of HCC, while some studies even reported better survival for young 
people (Abbas et al. 2008 and Zhang et al. 2014). 
The symptoms of upper abdominal pain and yellowness of the sclera 
and clinical examination finding of jaundice were significantly associated with 
early death. The explanation for these might be that these patients probably 
had ruptured liver nodule and probably had bleeding into the liver or 
peritoneum; both conditions could lead to early death.  Also, the complication 
of portal vein thrombosis was common among those that survived for long. 
This finding is at variance with the report by Chang et al. (2008) that long term 
survivors of HCC had less incidence of portal vein thrombosis. The number 
of cases with this condition was small and not statistically significant; 
therefore, we cannot make a strong statement out of it. 
The median survival using the CTP class showed that the survival of 
cases in this study is shorter than that reported by Cabibo et al. (2012) among 
untreated cases where those in CTP class C survived for a median period of 
3.7 months.  
The mean age of patients with HCC in this study differs from cases of 
HCC from other studies outside Nigeria (Ahmadzadehfar et al. 2014, Park et 
al. 2015 and Debes et al. 2018).  HCC occurred at a lower mean age in Nigeria 
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which is different from HCC from America mostly caused by HCV (Park et 
al. 2018), but close to those in Asia which is due to HBV. The lower mean age 
in Nigeria is probably due to the age at infection of HBV, and low HBV 
vaccine coverage (Sadoh et al. 2014).  Also, more males than females had 
HCC probably because males are more exposed to HBV and alcohol 
consumption, and cytokines may also play a role (Gomes et al. 2013). 
The age group of 41 years and above had more cases of HCC and this 
agrees with reports from within and outside Nigeria (Neef et al. 2009, 
Okonkwo et al. 2011, Yang et al. 2017, and Debes et al. 2018). The high 
incidence in this age group might be the age at infection of HBV and the length 
of time it takes for cancer to develop in a person infected with HBV.               
HBsAg positive test was seen more among young cases and this agrees 
with reports from Asia that HCC among young people is commonly due to 
HBV infection (Debes et al. 2018). The result of HCV showed that the virus 
does not play any significant role in the aetiology of HCC from the findings 
in this study. This study found that 13.4% cases of HCC had significant 
alcohol consumption. This shows that alcohol is a strong etiological factor. 
This study also reported that 22.8% took local herbal preparations; some 
herbal preparations contain multiple hepatotoxins and cause direct liver injury 
(Firenzuoli et al. 2013, Amadi et al. 2018). This is an area for further studies. 
In conclusion, factors associated with survival outcome of cases of HCC 
included elevated values of AST, ALT, total and conjugated bilirubin, alkaline 
phosphatase, creatinine and hyponatremia. Clinical findings revealed that 
those with jaundice and abdominal pain also had short survival period. 
Survival is also affected by sex and age of patients. Higher proportion of 
young cases of HCC were HBsAg positive. HBV and alcohol remain strong 
etiological factors. The number surviving beyond the first one month after 
diagnosis calls for serious concern. Therefore, preventive strategies targeting 
HBV and alcohol use reduction and early diagnosis of HCC toward aggressive 
curative treatment are advocated.          
                           
Limitations and strength of this study 
This study is among the first few prospective cohort studies on HCC 
in Nigeria. It is also among the first few survival studies that examined factors 
affecting survival of HCC patients on supportive care.  Those that were lost to 
follow up were censored in the Kaplan Meier survival analysis. In addition, 
history obtained from patients and phone calls to their relations assumed that 
they had given a true account of the cases.       
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